New drug could shield kids with cancer from chemo infections
NCT ID NCT04570423
First seen Oct 31, 2025 · Last updated Jun 20, 2026 · Updated 31 times
Summary
This study tests a drug called eflapegrastim in 40 children with solid tumors or lymphoma who are receiving chemotherapy. The drug aims to increase white blood cell counts, lowering the risk of severe infections. Researchers are checking how safe the drug is and how the body processes it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Carolinas Medical Center/ Levine Children's Hospital
TERMINATEDCharlotte, North Carolina, 28203, United States
-
Levine Children's Health
TERMINATEDCharlotte, North Carolina, 28203, United States
-
New York Medical College
TERMINATEDValhalla, New York, 10595, United States
-
UT MD Anderson Cancer Center
TERMINATEDHouston, Texas, 77030, United States
-
University Hospitals Cleveland Medical Center
RECRUITINGCleveland, Ohio, 44106, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
eflapegrastim (a drug to boost white blood cell production)
What this could lead to
If it works, this could offer a safer way to prevent serious infections in children undergoing chemotherapy for cancer.
What could go wrong
This is a small, early-phase study (40 children) focused on safety and drug levels, not yet on effectiveness. The drug may not reduce infections as hoped, and side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.